Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SSY Group ( (HK:2005) ) has issued an update.
SSY Group has strengthened its pediatric portfolio by becoming the first Chinese entity to secure production and registration approval for a fat-soluble vitamin injection for infants and children, covering vitamins A, D2, E and K1 via intravenous infusion. This move underscores the company’s push into specialized nutritional therapies and enhances its differentiation in the hospital injection market.
The group also obtained Chinese regulatory approvals for metformin hydrochloride tablets for type 2 diabetes and doxazosin mesylate extended release tablets for benign prostatic hyperplasia and hypertension, all passing consistency evaluation standards. These new approvals, alongside its previously cleared doxazosin bulk drug, broaden SSY’s chronic disease offerings and support its competitiveness in China’s increasingly quality-focused generic drug landscape.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a China-based pharmaceutical company focused on developing and manufacturing injectable and oral medications. The group targets key therapeutic areas such as pediatrics, endocrinology and chronic disease management, supplying both finished dosage forms and bulk drugs to the domestic healthcare market.
Average Trading Volume: 9,836,963
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.76B
Find detailed analytics on 2005 stock on TipRanks’ Stock Analysis page.